Effectiveness of a bivalent haemophilus influenzae type b-hepatitis B vaccine in preventing hepatitis B virus infection among children born to hepatitis B e antigen-positive carrier mothers

Pediatric Infectious Disease Journal

Volumn 28, Issue 9, 2009, Pages 777-781

  Doherty, Richard ^a   Garland, Suzanne ^b   Wright, Martin ^c   Bulotsky, Monique ^d   Liss, Charles ^e   Lakkis, Hassan ^e   Nikas, Alexander ^d   Straus, Walter ^d,e  

^a MONASH UNIVERSITY   (Australia)

^b ROYAL WOMEN'S HOSPITAL   (Australia)

^c SUNSHINE HOSPITAL   (Australia)

^d Departments of Microbiology and Epidemiology   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Hepatitis B; Protective effectiveness; Vaccine

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ABSENCE OF SIDE EFFECTS; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; CHILD; CHRONICITY; DNA ISOLATION; DRUG EFFICACY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; OBSERVATIONAL STUDY; PATIENT SAFETY; PRESCHOOL CHILD; PRIORITY JOURNAL; REVACCINATION; VIRUS CARRIER; VIRUS LOAD;

EID: 70249086999     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181a06fad     Document Type: Article

References (27)

1. Beasley RP, Hwang LY, Lee GC, et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet. 1983;2:1099-1102.
2. Lo KJ, Tsai YT, Lee SD, et al. Immunoprophylaxis of infection with hepatitis B virus in infants born to hepatitis B surface antigen-positive carrier mothers. J Infect Dis. 1985;152:817-821.
3. Pongpipat D, Suvatte V, Assateerawatts A. Perinatal transmission of hepatitis B virus in Thailand. Asian Pac J Allergy Immunol. 1985;3:191-193.
4. Xu ZY, Liu CB, Francis DP, et al. Prevention of perinatal acquisition of hepatitis B virus carriage using vaccine: preliminary report of a randomized double-blind placebo-controlled and comparative trial. Pediatrics. 1985;76: 713-718.
5. Centers for Disease Control and Protection. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the ACIP. Part 1: immunization of infants, children, and adolescents. MMWR. 2005;54(RR 16).
6. West DJ, Calandra GB. Vaccine induced immunologic memory for hepatitis B surface antigen: implications for a policy on booster vaccination. Vaccine. 1996;14:1019-1027
7. Centers for Disease Control and Prevention. Notice to readers: availability of hepatitis B vaccine that does not contain thimerosal as a preservative. MMWR. 1999;48:780-782.
8. West DJ, Hesley TM, Jonas LC, et al. Safety and immunogenicity of a bivalent Haemophilus influenzae type b/hepatitis B vaccine in healthy infants. Pediatr Infect Dis J. 1997;16:593-599.
9. Halsey NA, Blatter M, Bader G, et al. Inactivated poliovirus vaccine alone or sequential inactivated and oral poliovirus vaccine in two, four- and six-month-old infants with combination Haemophilus influenzae type b/hepatitis B vaccine. Pediatr Infect Dis J. 1997;16:675-679.
10. West DJ, Rabalais GP, Watson B, et al. Antibody responses of healthy infants to concurrent administration of a bivalent Haemophilus influenzae type b-hepatitis B vaccine, with diphtheria-tetanus-pertussis, polio, and measles-mumps-rubella vaccines. BioDrugs. 2001;15:413-418.
11. Hesley TM, Reisinger KS, Sullivan BJ, et al. Concomitant administration of a bivalent Haemophilus influenzae type b-hepatitis B vaccine, measles-mumps-rubella vaccine and varicella vaccine: safety, tolerability, and im-munogenicity. Pediatr Infect Dis J. 2004;23:240-245.
12. Ayres A, Locarnini S, Bartholomeusz A. HBV genotyping and analysis for unique mutations. Methods Mol Med. 2004;95:125-149.
13. Hall TA. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl Acids Symp. 1999;41:95-98.
14. Jennison C, Turnbull B. Group Sequential Methods with Applications to Clinical Trials. Boca Raton, FL: Chapman and Hall; 2000:235-257.
15. Hsu HM, Lee SC, Wang MC, et al. Efficacy of a mass hepatitis B immunization program after switching to recombinant hepatitis B vaccine: a population-based study in Taiwan. Vaccine. 2001;19:2825-2829.
16. Stevens CE, Toy PT, Taylor PE, et al. Prospects for control of hepatitis B virus infections: implications of childhood protection and long-term protection. Pediatrics. 1992;90:170-173.
17. Bauer T, Weinberger K, Jilg W. Variants of two major T cell epitopes within the hepatitis B surface antigen are not recognized by specific T helper cells of vaccinated individuals. Hepatology. 2002;35:455-465.
18. Ghany MG, Ayola B, Villamil FG, et al. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology. 1998;27:213-222.
19. Carman WF, Zanetti AR, Karayiannis P, et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet. 1990;336:325-329.
20. Protzer-Knolle U, Naumann U, Bartenschlager R, et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology. 1998;27:254-263.
21. Kfoury Baz EM, Zheng J, Mazurak K, et al. Characterization of a novel hepatitis B virus mutant: demonstration of mutation-induced hepatitis B virus surface antigen group specific ?a? determinant conformation change and its application in diagnostic assays. Transfus Med. 2001;11:355-362.
22. Jilg W, Schmidt M, Deinhardt F. Four-year experience with a recombinant hepatitis B vaccine. Infection. 1989;17:70-76.
23. Roome AJ, Walsh J, Cartter ML, et al. Hepatitis B vaccine responsiveness in Connecticut public safety personnel. JAMA. 1993;270:2931-2934.
24. Maynard JE. Hepatitis B: global importance and need for control. Vaccine. 1990;8(suppl):S18-S23.
25. Chang MH, Chen TH, Hsu HM, et al. Prevention of hepatocellular carcinoma by universal vaccination against hepatitis B virus: the effect and problems. Clin Cancer Res. 2005;11:7953-7957.
26. Hsu HY, Chang MH, Chen DS, et al. Baseline seroepidemiology of hepatitis B virus infection in children in Taipei, 1984: a study just before a mass hepatitis B vaccination program in Taiwan. J Med Virol. 1986;18: 301-307.
27. Stevens CE, Taylor PE, Tong MJ et al. Prevention of perinatal hepatitis B virus infection with hepatitis B immune globulin and hepatitis B vaccine. In: Zuckerman AJ, ed. Viral Hepatitis and Liver Disease. New York, NY: Alan R. Liss;1988:982-988